Back to results
US 2021/0198368 A1Published application
Multispecific molecules targeting cll-1
AssigneeNovartis AG
InventorsMichael DALEY, Hilmar EBERSBACH, Julia JASCUR, Qilong WU, Qiumei YANG, Jiquan ZHANG
Life of this patent
Estimating the term…
Abstract
The present invention is directed to multispecific/multivalent molecules comprising an anti-CLL-1 binding domain.
Claims65
A multispecific molecule comprising a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain is an anti-CLL-1 binding domain comprising:
- (i) (a) a heavy chain complementary determining region 1 (HC CDR1) of SEQ ID NO:
- 317, (b) a heavy chain complementary determining region 2 (HC CDR2) of SEQ ID NO:
- 331, (c) a heavy chain complementary determining region 3 (HC CDR3) of SEQ ID NO:345 and (d) a light chain complementary determining region 1 (LC CDR1) of SEQ ID NO:
- 359, (e) a light chain complementary determining region 2 (LC CDR2) of SEQ ID NO:373, and (f) a light chain complementary determining region 3 (LC CDR3) of SEQ ID NO:387;
- (ii) (a) a HC CDR1 of SEQ ID NO:315, (b) a HC CDR2 of SEQ ID NO:329, (c) a HC CDR3 of SEQ ID NO:343 and (d) a LC CDR1 of SEQ ID NO:
- 357, (e) a LC CDR2 of SEQ ID NO:
- 371, and (f) a LC CDR3 of SEQ ID NO:
- 385;
- or
- (iii) (a) a HC CDR1 of SEQ ID NO:321, (b) a HC CDR2 of SEQ ID NO:335, (c) a HC CDR3 of SEQ ID NO:349 and (d) a LC CDR1 of SEQ ID NO:363, (e) a LC CDR2 of SEQ ID NO:377, and (f) a LC CDR3 of SEQ ID NO:391.
7 more elements
-4. (canceled)
(canceled)
-29. (canceled)
-81. (canceled)
Dependencies are inferred from the claim text.